Mazen Darwazah

All filings by Mazen Darwazah on record concern Hikma Pharmaceuticals PLC. The record holds 21 filings, for trades running from 31 March 2016 to 1 June 2026.

Purchases make up the whole of the open-market record (14 purchases, €19.9M). The totals exclude 5 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 7 share grants. In 2026 alone, the filings show 2 purchases and no sales.

The median purchase comes to €1.7M. Of 9 purchases, 5 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 4 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -9.6%. These figures describe past trades and do not predict future prices.

On 5 June 2026 came the latest disclosure, an open-market purchase in Hikma Pharmaceuticals PLC. Filings reach the RNS (LSE) feed a median of 1 day after the trade. The regulation allows three business days to notify a trade (UK MAR). These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.